KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancers (Basel)
Päätekijät: Ghimessy, Áron Kristof, Gellert, Áron, Schlegl, Erzsebet, Hegedus, Balazs, Raso, Erzsebet, Barbai, Tamas, Timar, Jozsef, Ostoros, Gyula, Megyesfalvi, Zsolt, Gieszer, Balazs, Moldvay, Judit, Renyi-Vamos, Ferenc, Lohinai, Zoltan, Hoda, Mir Alireza, Klikovits, Thomas, Klepetko, Walter, Laszlo, Viktoria, Dome, Balazs
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827133/
https://ncbi.nlm.nih.gov/pubmed/31600989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101514
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia